Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio
- PMID: 27552856
- DOI: 10.1016/j.cgh.2016.08.019
Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio
Comment in
-
Reply.Clin Gastroenterol Hepatol. 2017 Jan;15(1):148-149. doi: 10.1016/j.cgh.2016.09.016. Epub 2016 Sep 17. Clin Gastroenterol Hepatol. 2017. PMID: 27650327 No abstract available.
Comment on
-
Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease.Clin Gastroenterol Hepatol. 2016 Jul;14(7):966-972.e2. doi: 10.1016/j.cgh.2015.10.034. Epub 2015 Nov 18. Clin Gastroenterol Hepatol. 2016. PMID: 26598226
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical